Trial Profile
A Multicenter, Randomized, Double-Blind, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-Dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Idrabiotaparinux sodium (Primary) ; Avidin; Warfarin
- Indications Stroke; Thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms BOREALIS-AF
- Sponsors Sanofi
- 05 Oct 2021 This trial has been completed in Spain (End Date: 08 Oct 2010), according to European Clinical Trials Database record.
- 05 Mar 2014 Results published in the Journal of Thrombosis and Haemostasis.
- 26 Oct 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.